TCIM
RUBY

TIAA CREF Investment Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

TIAA CREF Investment Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.16M Buy
63,855
+47,528
+291% +$729K ﹤0.01% 2249
2018
Q4 		$263K Hold
16,327
– – ﹤0.01% 2808
2018
Q3 		$392K Buy
+16,327
New +$373K ﹤0.01% 2809

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

TIAA CREF Investment Management's RUBY Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Rubius Therapeutics, Inc (RUBY) stake by 291% in Q1 2019, buying an estimated $729K and bringing the position to 63,855 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

TIAA CREF Investment Management first reported a position in RUBY in Q3 2018 and has held it in 3 quarters since. 67 funds tracked by Wall St. Rank hold RUBY as of Q1 2019.

  • TIAA CREF Investment Management held 63,855 shares of Rubius Therapeutics, Inc worth $1.16M as of Q1 2019.
  • TIAA CREF Investment Management bought 47,528 Rubius Therapeutics, Inc shares in Q1 2019, an estimated $729K.
  • Rubius Therapeutics, Inc made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2249 holding.
  • TIAA CREF Investment Management first reported a position in Rubius Therapeutics, Inc in Q3 2018 and has held it in 3 quarters since.
  • 67 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.